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ABSTRACT
Adenoviruses are lytic DNA viruses that are ubiquitous in human communities. In total, 51 different serotypes
with varying tissue tropisms have been identified. Adenovirus infections, although frequent, are rarely fatal in
immunocompetent individuals who have potent innate and adaptive immunity. But in immunosuppressed
individuals, adenoviruses are a significant cause of morbidity and mortality, with limited treatment options. In
particular, pediatric recipients of allogeneic hematopoietic stem cell transplantation frequently develop infec-
tions early in the posttransplantation period. Because the endogenous recovery of adenovirus-specific T cells
has proven important in controlling infection, we explore the potential of adoptive T-cell immunotherapy as
a therapeutic strategy. We discuss the advantages and limitations of T-cell therapy for the prophylaxis and
treatment of adenovirus infection posttransplantation.
© 2006 American Society for Blood and Marrow Transplantation
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Adenoviruses are ubiquitous, nonenveloped, lytic
NA viruses. The 51 different human serotypes have
een divided into 6 species (formerly called subgroups),
–F, based on their hemagglutination properties, on-
ogenic potential in rats, and DNA homology (Table 1).
nfection occurs by receptor-mediated endocytosis,
ith most human adenoviruses entering their target
ells through a primary binding interaction between
he ﬁber protein on the virus capsid and the Cox-
ackie-adenovirus receptor (CAR). The exceptions to
his rule include species B viruses, which interact with
arget cells through CD46 [1,2], and the species D
erotypes 8, 19a, and 37, which bind to sialic acid
esidues rather than to CAR on target cells [3]. Pri-
ary binding is followed by a secondary interaction
ediated by the penton base of the virus and speciﬁc
ntegrins on the target cell surface. Once species C
denoviruses have been internalized, they travel to
arly endosomes, from where they escape to the cy-
osol in an active process triggered by the acidity of
his compartment [4]. The adenoviral particles then g
B&MTigrate to the nucleus using the cellular microtubule
etwork, where they bind to the nuclear pore com-
lexes and translocate the viral genomes to the nucleus
llowing the viral genes to be expressed [5-8]. The in-
racellular trafﬁcking route is determined by the ﬁber
nob domain and by the nature of the primary attach-
ent receptor [4,9,10]. Using ﬁber-chimeric vectors,
hayakhmetov et al. [4] demonstrated that Ad5f35
articles gain access to the nucleus by remaining in-
ide late endosomes. During this process, some or all
f the virion proteins gain access to major histocom-
atibility complex (MHC) class I and II processing
athways, so that infected cells become sensitive to
denovirus-speciﬁc T-cell recognition even in the ab-
ence of subsequent virus gene expression. Ultimately,
he replication of viral DNA coupled with the produc-
ion of large quantities of adenovirus structural polypep-
ides sets the stage for viral assembly and eventual
scape from the host cell (Figure 1).
The viral genome codes for more than 30 struc-
ural and nonstructural proteins [11]. The non-
tructural proteins can be broadly divided into 2
roups, early and late gene products. Early viral
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2ene products mediate viral gene expression and
NA replication, induce cell cycle progression,
lock apoptosis, and antagonize various host antivi-
al measures, whereas late gene products promote
irus assembly and escape. Adenovirus has sophis-
icated mechanisms for evading both the innate and
daptive host immune systems and devotes a large
ortion of its genome to this purpose [12,13]. The
arly protein E1A and the VA (virus-associated)
NAs block responses to interferons (IFNs),
hereas E1B inhibits cellular apoptosis induced by
he stress of the virus infection. The evasion genes
ncoded in the E3 region have various functions,
ncluding tethering MHC I molecules in the endo-
lasmic reticulum and inhibiting the tapasin trans-
orter that processes peptides for presentation on MHC
olecules. Both processes combine to prevent recogni-
ion and lysis of infected cells by cytotoxic T lympho-
able 1. Adenovirus Species and Serotypes
Species Tissue Tropism Serotypes
Gastrointestinal tract 12, 18, 31
Urinary tract, Lung 3, 7, 11, 14, 16, 21,
34, 35, 50
Respiratory tract 1, 2, 5, 6
Eye, gastrointestinal tract 8-10, 13, 15, 17, 19,
20, 22-30, 32, 33,
36-39, 42-49, 51
Respiratory tract 4
Gastrointestinal tract 40, 41
igure 1. Adenovirus life cycle. Infection is a multistage process
resentation, trafﬁcking to the nucleus, viral replication, and ﬁnally
nd antigen presentation may occur before the expression of the im
ntry into the nucleus. Thus the infected cell may be sensitive to ly
nfectious virions.
44ytes (CTLs). In addition, E3 proteins inhibit tumor
ecrosis factor (TNF)-, Fas, and TRAIL-induced cell
eath by removing their receptors from the infected
ell surface, thus rendering the cells invisible to acti-
ated CTLs and monocytes [12-16].
Both innate and adaptive immune responses are
lerted by the infection process before the expression
f immune evasion genes. The innate immune re-
ponse represents the ﬁrst line of defense against in-
ading pathogens, which are recognized through a
umber of receptors in intracellular and extracellular
ompartments. The most-studied family of recognition
eceptors is the Toll-like receptor family, although other
echanisms of pathogen recognition exist. Ultimately,
ecognition of pathogen-associated molecular patterns
riggers a series of events, including activation of
F-B and signal transduction through the mitogen-
ctivated protein kinases. These signals determine the
ype of immune response that will be produced and
esult in the transcription of host chemokines, includ-
ng macrophage inﬂammatory protein (MIP)-2, IFN-–
nducible protein 10, MIP-1, RANTES, and cyto-
ines such as interleukin (IL)-1, IL-6, IFN-, and
NF-. These molecules may have a direct antiviral
esponse and also recruit and activate innate effector
ells, such as natural killer cells, granulocytes, and
onocytes, to sites of infection [17,18]. Subsequently,
he adaptive immune response, mediated by T and B
ells [19-22], is activated.
ng adsorption, internalization, virus uncoating and virion antigen
ell lysis and virus escape. The ﬁgure indicates that virus uncoating
evasion genes, which occurs in a temporal fashion after viral DNA
virion-speciﬁc T cells before its production and the release of newinvolvi
host c
mune
sis by
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Adenoviral Infections in Hematopoietic Stem Cell Transplantation
BATHOLOGY AND DIAGNOSIS
Many adenovirus serotypes cause morbidity and
ortality in immunosuppressed individuals. The most
ommonly isolated serotypes are 1, 2, and 5 from
pecies C and 34 and 35 from species B [23]. Although
nfection, signiﬁed by detection of viral DNA, is not
lways associated with disease, disease is associated
ith signiﬁcant mortality, and antiviral therapies have
imited efﬁcacy against adenovirus.
Detection and treatment of adenovirus infections
n immunocompromised patients is dependent on a
ensitive means of viral identiﬁcation, because adeno-
irus may be responsible for a wide range of clinical
yndromes, including pneumonia, gastroenteritis, hepa-
itis, hemorrhagic cystitis, nephritis, encephalitis, and
yocarditis, which are common manifestations of other
ost–bone marrow transplantation complications [23].
ifferent tissues, most commonly stool, urine, blood,
nd nasal washes, must be analyzed and a variety of
ethods have been used to diagnose adenovirus con-
lusively. Until recently, culturing adenovirus was the
ost commonly used method of detection. However,
t may take up to 3 weeks for a cytopathic effect to
evelop, and some serotypes require special cell lines
or isolation. Because early treatment with antiviral
gents has a better outcome, a rapid diagnosis is re-
uired. For this reason, several groups have developed
onventional, nonquantitative polymerase chain reac-
ion (PCR) assays for the detection of adenovirus in
linical samples [24-27].
Viral quantiﬁcation in clinical samples is standard
ractice for a number of different human viruses using
eal time PCR (RT-PCR) protocols [28-31]. But such
protocol is complicated for adenovirus, because of
he wide range of serotypes and the consequent difﬁ-
ulty ﬁnding conserved sequences for primer/probe
election. Heim et al. [32] addressed this problem by
esigning consensus primer sequences capable of an-
ealing to the hexon protein from all 51 different
erotypes. These authors screened 218 clinical samples
rom multiple sites, including blood, serum, eye
wabs, and feces, by conventional nonquantitative
CR and RT-PCR and found divergent results in 16
amples (15 positive only by RT-PCR and 1 positive
nly by conventional PCR). All of the samples that
ere positive by RT-PCR but negative by conven-
ional PCR had adenovirus DNA concentrations 103
opies/run, indicating a lower sensitivity of the con-
entional PCR. Lion et al. [33] reﬁned this approach
y designing RT-PCR primer/probe combinations
erived from both hexon and the VA RNA region,
ith the ability to distinguish between the 6 different
denovirus species. Identiﬁcation of the infecting spe-
ies may prove important, particularly if different ad-
novirus species are differentially sensitive to antiviral
gents [34]. These RT-PCR protocols will likely be- c
B&MTome standard of care in the hematopoietic stem cell
ransplantation (HSCT) setting.
DENOVIRUS INFECTIONS IN HEMATOPOIETIC STEM
ELL TRANSPLANTATION RECIPIENTS
Various retrospective and prospective studies have
een carried out to assess the incidence of adenovirus
nfection and disease in both adult and pediatric trans-
lantation recipients and also to identify risk factors
or the development of adenovirus infection and dis-
ase posttransplantation [35]. Rates of post–HSCT
nfection varying from 5% to 32% have been reported
33,36-41], but this broad range is likely due to differ-
nt monitoring assays with differing sensitivities used
y the various transplantation centers. Thus there is a
eed for standardization in adenovirus detection
ethods to deﬁnitively quantitate the incidence of
denovirus infections posttransplantation. The inci-
ence of disease in patients with detectable adenovirus
n peripheral blood can be as high as 73% [33].
Numerous groups have also attempted to identify
actors that are predictive of adenovirus infection
nd/or disease development [35]. Lion et al. [33] found
hat repeated detection of adenovirus in peripheral
lood using RT-PCR and rising viral load provided
he most reliable means of diagnosing infection and
redicting disease. Runde et al. [41] suggested that
denovirus antibodies in the donor, indicating a recent
xposure, may also be a signiﬁcant risk factor in the
evelopment of infection. This ﬁnding suggests that
denovirus infections post-HSCT are not always reac-
ivations or new infections, but also may be transmit-
ed from the donor; however, this has yet to be for-
ally demonstrated.
The incidence of adenovirus infection is highest in
hildren undergoing allogeneic transplantation and
owest in adults and in children undergoing autolo-
ous transplantation [33,36-40,42]. This difference
ay be linked to the repertoire of the immune re-
ponse to adenovirus in adults and children. Adenovi-
us is ﬁrst encountered during childhood, during
hich infections are frequently associated with species
viruses, so that the immune response in the early
ears may be quite species-speciﬁc. However, over
ime, the breadth of exposure to different species in-
reases, so that immunity broadens, and, in adults,
pecies cross-reactive CTLs that can recognize all
pecies of adenovirus circulate in the periphery more
requently than serotype-speciﬁc CTLs [19,20,44,45].
hus the higher incidence of infection early in the
osttransplantation period in children may reﬂect a
ack of species cross-reactive T cells. If this were the case,
hen risk would be expected to relate to the donor’s
revious exposure; however, the question of whether
hildren receiving sibling stem cells are at greater risk of
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2eveloping an adenovirus infection than those receiv-
ng adult stem cells has yet to be addressed. A major
ifference between pediatric and adult transplantation
ecipients relates to the median time of detection
90 days posttransplantation in adults, compared
ith 30 days posttransplantation in children)
36,39,42].
Once an adenovirus infection has been identiﬁed,
reatment options are limited. The antiviral agents
ibavirin and cidofovir can be administered in combi-
ation with tapering immunosuppression [37,40,43].
owever, antivirals have controversial efﬁcacy in vivo
as reviewed in the next section), and in some circum-
tances it is not feasible to taper immunosuppression
ecause of the risk of graft-versus-host disease. Be-
ause resolution of adenovirus infections and disease
as been shown to coincide with the recovery of en-
ogenous T-cell function [46,47], adoptive immuno-
herapy with adenovirus-speciﬁc T cells that have been
ctivated and expanded in vitro remains a viable (al-
hough as-yet untested) possibility. In the absence of
herapeutic alternatives, various groups are currently
orking on developing such protocols, as discussed in
ore detail in the Immunotherapy section.
ROPHYLAXIS/THERAPY WITH ANTIVIRAL AGENTS
Adenovirus infections are common after alloge-
eic HSCT, and most patients are able to eliminate
he virus without treatment, as recently demonstrated
n a retrospective study by Walls et al. [48]. These
uthors analyzed 273 samples from 26 pediatric pa-
ients by PCR and found that 7 of 11 children with
lood samples that were positive for adenovirus by
CR cleared the virus without antiviral therapy. How-
ver, it is difﬁcult to predict which patients will spon-
aneously clear an infection and which patients will
uccumb to adenovirus disease. Treatment options are
imited for the latter group. The choice of antiviral
gents is restricted to ribavirin and cidofovir, but to
ate no study has conclusively demonstrated the efﬁ-
acy of these agents as prophylaxis/treatment for ad-
novirus infection and/or disease [49-54].
Ribavirin, a guanosine analog with broad antiviral
ctivity, has been used as a treatment for adenovirus
nfections and disease with variable results. Recently,
ankaster et al. [54] examined 4 pediatric patients who
eveloped adenoviremia post-allogeneic HSCT and
ho received ribavirin at the ﬁrst sign of dissemina-
ion. After antiviral treatment, viral load was measured
sing real-time PCR analysis. In all 4 cases ribavirin
as not associated with a decrease in viral load, and in
act an increase was noted in 3 of the 4 patients [55].
hus it would seem that ribavirin lacks signiﬁcant
ntiviral activity in vivo. On the basis of this observa-
ion, treatment was switched from ribavirin to cido- e
46ovir in 2 of the patients, resulting in stabilization of
n already extremely high viral load. Both patients
ventually succumbed to disease, however.
Cidofovir is a nucleotide analog with potent in vitro
eactivity against several DNA viruses. Its successful use
n treating adenovirus infection and/or disease posttrans-
lantation was reported by Bordigoni et al. [49]. Leruez-
ille et al. [56] evaluated clinical symptoms and virus
oad in response to cidofovir in 8 immunosuppressed
atients with invasive adenovirus disease and found
hat 5 patients had clinical improvement and a con-
urrent reduction in viral load with good outcomes,
ut the remaining 3 did not respond and died, 2 due to
denovirus disease and 1 due to multiple infections and
raft rejection. It should be noted that cidofovir treat-
ent was started later for the 3 patients who died (a
edian of 18 days after the development of symptoms,
ompared with 8 days in those who responded) [56].
hus it appears that cidofovir may be more efﬁcacious
n vivo than ribavirin in treating established adenovi-
us disease. But the time interval between the onset of
ymptoms and administration of treatment may be
rucial, and the nephrotoxicity associated with intra-
enous cidofovir treatment remains a major concern. A
rospective randomized, controlled trial is needed to
onﬁrm efﬁcacy in vivo, because rapid spontaneous
learance can coincide with immune recovery post-
SCT.
ELLULAR IMMUNE RESPONSES TO ADENOVIRUS
A number of studies have linked the incidence of
denovirus disease in HSCT recipients with the lack of
ecovery of antigen-speciﬁc T cells [37,43,46,47,57,58];
owever, to date there are no reports of immunother-
py trials for the prophylaxis and treatment of adeno-
irus infections in immunocompromised patients.
onetheless, as proof of principle, one group has
eported the efﬁcacy of donor leukocyte infusion for
he treatment of disease [59]. Accordingly, a number
f groups have begun to analyze the T-cell immune
esponse to adenovirus, with a view to identifying
ational targets for future clinical trials. Early studies
f human immunity to adenovirus, carried out by
lomenberg et al. [22,60], showed that the adenovirus-
peciﬁc cellular immune response is mainly CD4 me-
iated and appears to be cross-reactive among different
pecies. An adenovirus-reactive CD8 T-cell compo-
ent was also detected in later studies [14]. Subse-
uently, Smith et al. demonstrated CD4 and CD8
denovirus-speciﬁc T cell responses to dendritic cells
nfected with either wild-type Ad5 or Ad5 dl312, an
1A-deleted mutant, which expresses few if any viral
enes [61], implying that at least one of the input
irion proteins was stimulating memory T cells. Regn
t al. [62] developed a CD40–ligand co-culture system
t
l
e
v
e
s
v
C
d
e
H
t
a
a
e
t
b
p
r
m
c
[
p
v
a
s
h
w
m
o
c
b
v
i
w
t
i
T
d
T
g
T
t
p
l
A
d
s
i
a
c
r
t
t
[
c
c
r
l
f
u
u
o
v
i
v
a
w
e
c
l
A
w
a
r
p
c
r
f
s
q
t
a
h
t
h
r
o
o
h
c
[
c
r
r
i
w
d
s
t
s
o
r
[
i
Adenoviral Infections in Hematopoietic Stem Cell Transplantation
Bo infect Epstein-Barr virus (EBV)-transformed B-cell
ines (LCLs) with adenovirus, then stimulated periph-
ral blood mononuclear cells from EBV- and adeno-
irus-seropositive donors weekly with autologous ad-
novirus-positive LCLs. Using this method, they were
uccessful in generating CTL lines speciﬁc for both
iruses, and the recognition was mediated by both
D4 and CD8T cells. Using dendritic cells trans-
uced with recombinant adenoviral vectors encoding
ither cytomegalovirus (CMV) pp65 or EBV EBNA3C,
amel et al. [63] also generated polyclonal CTL lines
hat were bi-virus reactive. However, the response
gainst the adenovirus component was less than that
gainst pp65 or EBNA3C, suggesting either that ad-
novirus is not as immunogenic as EBV and CMV, or
hat the exogenous antigen-processing pathway used
y adenovirus was less potent than the endogenous
athway used by the transgenes. Importantly, adenovi-
us-speciﬁc polyclonal T cells, activated by different
ethodologies, were able to recognize and kill target
ells infected with viruses from multiple species
14,19,44,45,61].
More recently, various groups have begun map-
ing T-cell target antigens in adenovirus. When in-
estigating whether the virion proteins hexon, penton,
nd ﬁber were responsible for stimulating adenovirus-
peciﬁc T cells in vitro, Hamel et al. [63] found that
exon was strongly immunogenic in most donors,
hereas penton and ﬁber were found to be less im-
unogenic. Hexon is the largest and most abundant
f the structural proteins in the icosahedral adenoviral
apsid. The other two major capsid proteins, penton
ase and ﬁber, form the penton complex at each virion
ertex. Thus it seems that the T-cell immune response
s polarized to these abundant structural antigens,
hich are readily available for processing and presen-
ation to circulating T cells before the expression of
mmune evasion genes [64]. The ﬁne mapping of
-cell peptide epitopes in adenovirus is also being
one by various groups, and a hexon-speciﬁc CD4
-cell epitope has been described [21,65], whereas our
roup has identiﬁed multiple hexon-speciﬁc CD8
-cell epitopes [44]. These studies have provided po-
ential target antigens for immunotherapy, as well as
eptide and tetramer/multimer reagents for immuno-
ogic evaluation of T-cell infusions.
DENOVIRUS CROSS-REACTIVITY
Antibody responses to adenovirus can be broadly
ivided into 2 types: species-speciﬁc reactivity and type-
peciﬁc reactivity. Generally, species-speciﬁc antibod-
es are nonneutralizing, whereas type-speciﬁc responses
re directed against hypervariable regions on the virus
apsid and can effectively neutralize extracellular vi-
us, thus preventing virus spread [66-69]. The main n
B&MTargets of type-speciﬁc neutralizing antibodies are
he adenovirus structural proteins, hexon and ﬁber
70,71].
T-cell reactivity in humans has also proven to be
ross-reactive, although most of this analysis has been
arried out in bulk CTL lines [21,45,60,61]. More
ecently, these studies have been reﬁned to a clonal
evel; Heemskerk et al. [19] analyzed CD4 clones
rom cross-reactive polyclonal CTL lines activated
sing inactivated Ad5 (species C) as an antigenic stim-
lus. Of 11 T-cell clones tested, 2 reacted only with
ther species C viruses, 4 reacted with species B and C
iruses, and 5 reacted with species A, B, and C viruses
n proliferation assays [19]. It should be noted that
iruses from species D, E, and F were not screened,
nd the antigen and epitope speciﬁcity of the clones
as not identiﬁed.
Our group has also addressed the question of ad-
novirus cross-reactivity using a panel of CD8 T-
ell clones generated from a cross-reactive polyclonal
ine, reactivated with a replication-defective chimeric
d5f35 vector [20,72,73]. The CD8 T-cell clones
ere reactive against 5 hexon-speciﬁc T-cell epitopes
s assessed by cytotoxicity assay. Four of these epitopes,
estricted by HLA-A*1, HLA-A*2, and HLA-B*7, were
rocessed and presented in a species B, C, D, and E
ross-reactive manner, whereas the remaining epitope,
ecognized in the context of HLA-A*24, was speciﬁc
or viruses within species C and D. Viruses from
pecies A or F were not tested, but the epitope se-
uences were conserved within these species [44].
The hexon protein can be divided into two parts:
he loops on the outer surface of the molecule, which
re hypervariable, and the base of the protein, which is
ighly conserved because of packing constraints within
he capsid [11,68]. Examination of the location of our
exon-speciﬁc T-cell epitopes on the hexon molecule
evealed that all were located in the conserved region
f hexon, irrespective of whether reactive T cells rec-
gnized viruses from 2 species or 4 species. Thus, we
ypothesize that the adenovirus-speciﬁc memory T-
ell pool reﬂects the pattern of previous exposure
74,75]. We predict that after the ﬁrst exposure, T
ells will be speciﬁc for both type-speciﬁc and cross-
eactive epitopes; with subsequent infections, cross-
eactive T cells will be expanded preferentially, so that
n adults who have experienced multiple infections
ith various serotypes, cross-reactive epitopes will
ominate. Because the pool of adenovirus serotypes is
tably maintained in human populations and there is a
emporal infection pattern, with most common expo-
ure to species C viruses in childhood followed by
ther serotypes from the other species, species cross-
eactive immunity can be developed and maintained
70,71]. This may have implications for HSCT recip-
ents, because immunity transferred from younger do-
ors may be less broadly cross-reactive and less pro-
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2ective than that from older donors. However, this has
et to be addressed in clinical studies and in studies of
denovirus-speciﬁc immunity in children.
MMUNOTHERAPY
Adoptive immunotherapy has already proven suc-
essful as prophylaxis and treatment for EBV- and
MV-related infections and disease in HSCT recipi-
nts [76-81]. In vitro expanded CTLs have a number
f advantages over standard therapy, including their
ack of toxicity and ability to persist and protect during
he entire posttransplantation period [77,79], but they
resent both scientiﬁc and practical complexities.
irst, the T-cell line must be generated under good
anufacturing practices in a specialized cell culture
acility, which is available in few hospitals. Therefore,
he global usefulness of immunotherapy as an ap-
roach for the prophylaxis/treatment of viral infec-
ions is limited, although stem cell processing facilities
ay be adapted for cell culture. Any CTL expansion
rotocol must use approved reagents and supplies, and
lthough clinical grade products are not required for
hase I/II protocols, they must meet certain manufac-
uring requirements and be approved by federal reg-
latory agencies. Finally, the rules that govern the
eneration, safety testing, and infusion of such lines
re extensive to the point of being prohibitive, and the
ssociated expenses are considerable.
From a scientiﬁc standpoint, initiating adoptive
mmunotherapy protocols for adenovirus is compli-
ated, because adenovirus T-cell immunology is less
ell understood and it is unclear which target antigens
ill be protective in vivo. Experience in other systems
as indicated that a successful/efﬁcacious CTL prod-
ct should contain a combination of CD4 and
D8 T cells to promote in vivo persistence [77,82];
herefore, a simple and reliable method of activating
nd expanding adenovirus-speciﬁc polyclonal CD4
nd CD8 CTLs must be developed. Finally, to eval-
ate the efﬁcacy of T-cell infusions, it must be possi-
le to track their function and persistence over time
fter infusion.
Recent advances in our understanding of adeno-
irus immunogenicity, as well as increasing detection
f adenoviremia in immunosuppressed individuals,
ave spurred various groups to develop adenovirus-
doptive immunotherapy protocols that can be per-
ormed under good manufacturing practices and ap-
lied to a clinical setting. Feuchtinger et al. [57] took
dvantage of the IFN- secretion assay to isolate ad-
novirus-speciﬁc T cells from peripheral blood or
rom leukapheresis products. Peripheral blood mono-
uclear cells (0.1–2  109) were stimulated with an
denovirus lysate for 16 hours, and then cytokine-
ecreting cells (median, 3.4  106) were isolated using s
48he CliniMACS system. These cells were subsequently
xpanded in vitro using 100 U/mL of IL-2 and irra-
iated allogeneic feeders (5  106/mL) until there
ere sufﬁcient cells for infusion purposes. It took a
edian of 18 days to reach 108 total cells, and these
ere tested in various functional assays to conﬁrm the
peciﬁcity of the lines and to assess any residual allo-
eneic activity. The purity at the end of the expansion
hase was 85%, with some nonspeciﬁc reactivity re-
aining. Feuchtinger et al. [57] propose using this
ystem in future immunotherapy protocols, because it
s an easy and rapid method for isolating and expand-
ng antigen-speciﬁc T cells that may be applicable to
linical-grade applications. However, higher purity
ay be required at the initial isolation step to prevent
he carry-over of nonspeciﬁc T cells, and an alterna-
ive source of virus-free antigen may be required as a
timulus.
Our group has adopted a different approach to
denovirus-adoptive immunotherapy. We reasoned
hat because adenovirus structural proteins appear to
e immunogenic in vitro, they may provide sufﬁcient
ntigen stimulation to memory T cells. Adenoviral
ectors are readily available as a puriﬁed clinical-grade
roduct because they have been used for many years in
ene therapy studies and as vaccines [83]. We have
roduced a clinical-grade chimeric Ad5f35-null vector
hat, after transduction into activated monocytes, is
ble to reactivate hexon-speciﬁc T cells [20,44]. For
he in vitro expansion of the T cells, we used autolo-
ous Ad5f35 null-transduced LCL, which can readily
e produced from each donor, providing an unlimited
ource of APCs (antigen-presenting cells) that can
resent adenovirus proteins [20]. Although LCLs also
resent EBV antigens, they maintain the adenovirus-
peciﬁc T-cell component during the expansion pro-
ess with only minor expansion of residual EBV-spe-
iﬁc T cells that remain in the cultures after the ﬁrst
timulation with adenovirus-transduced monocytes
20]. Because allogeneic HSCT recipients are at risk
or both adenovirus and EBV, we reasoned that the
nfusion of a bi-virus–speciﬁc CTL line speciﬁc for
oth viruses would be a bonus. There are some limi-
ations associated with this method, most notably the
se of an LCL for the second and subsequent rounds
f expansion. In this situation the generation of an
CL line, rarely a problem in healthy bone marrow
onors, can take up to 6 weeks, causing a signiﬁcant
elay in the CTL generation process. Because adeno-
iral infections occur early in the posttransplantation
eriod, CTLs may be most effective when adminis-
ered at this time. Therefore, in the long term, other
ources of APCs, such as B-cell blasts or methods
sing artiﬁcial APCs for expansion, may be investi-
ated to speed up the CTL generation process.
A clinical protocol for the infusion of adenovirus-
peciﬁc CTLs into recipients of allogeneic HSCT was
s
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Bubmitted to and approved by the Baylor College of
edicine Institutional Review Board, the Recombi-
ant DNA Advisory Committee, and the US FDA.
atients will be enrolled on this study in the coming
onths, and we anticipate the patient cohort to be
ominated by pediatric patients undergoing allogeneic
ransplantation at Texas Children’s Hospital. Patients
ill receive CTLs regardless of adenovirus status on
nrollment. Although there may be too few patients in
his study to determine antiviral efﬁcacy, we will be
ble to evaluate the patients’ ability to reconstitute
mmune responses to adenovirus using immunologic
ssays. For this reason, we will preferentially enroll
atients with an informative HLA type, that is, for
hich we have identiﬁed epitopes. This will enable the
se of multimer and ELISPOT assays to track infused
cells in preinfusion and postinfusion blood samples
nd evaluate their ability to expand, reconstitute im-
unity to adenovirus, and persist in vivo.
Along with immunologic monitoring, extensive
irologic monitoring of patients for the presence of
BV and adenovirus preinfusion and postinfusion will
e performed using RT-PCR analysis of peripheral
lood for EBV and blood, urine, and stool samples for
denovirus. Initially, samples will be assessed for ade-
ovirus positivity using a generic primer–probe com-
ination that detects all adenovirus serotypes. If an
nfection is detected, then the infecting species will be
dentiﬁed using the primer–probe combination spe-
iﬁc to each species. This virologic monitoring will be
arried out pretreatment, then weekly for 60 days
ostinfusion, and then in accordance with the stan-
ard of care for each patient.
ERSPECTIVES
In summary, adenovirus infections remain a major
ause of morbidity and mortality, particularly in
SCT recipients. Although signiﬁcant advances have
een made in our ability to detect infection and even
o identify the infecting species, antiviral therapies are
acking. A number of recent publications have dem-
nstrated a link between the recovery of endogenous
denovirus-speciﬁc T cells and protection against in-
ection and disease in vivo. Consequently, protocols
or the infusion of in vitro expanded adenovirus-spe-
iﬁc T cells as prophylaxis and/or treatment for infec-
ion and disease are being developed by a number of
ranslational groups worldwide. This work is being
acilitated by the identiﬁcation of immunogenic ade-
ovirus antigens, which will provide rational targets
or in vivo studies. In addition, the list of adenovirus-
peciﬁc CD4 and CD8 T cell epitopes is growing,
llowing for the characterization of CTL lines prein-
usion and facilitating follow-up analysis postinfusion.
hus, while waiting for the identiﬁcation of novel and
B&MTontoxic antiviral agents that are effective against ad-
noviruses, adoptive T-cell therapy for adenovirus
ay provide the best treatment option available. Pro-
iding that the immunogenic antigens identiﬁed are
rotective, we can anticipate a signiﬁcant reduction in
he number of patients who succumb to adenovirus
nfections posttransplantation, as has been the case with
doptive immunotherapy for EBV.
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